Compare Ascendis Pharma A/S (ASND) vs Taskus Inc (TASK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Taskus Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Taskus Inc trades at $5.46 (market cap $495.44M). The key difference: Ascendis Pharma A/S is far larger — about 35.8× Taskus Inc's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Taskus Inc nearer its low. Which is the better fit depends on your goals.
| ASND | TASK | |
|---|---|---|
Market Cap | $17.74B | $495.44M |
Sector | Health | Technology |
52-Week High | $277.18 | $18.21 |
52-Week Low | $163.32 | $4.57 |
Enterprise Value | $18.11B | $891.14M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
TaskUs (TASK) trades at $5.41, up 2.66% today, with a neutral technical signal and bearish moving averages. The company shows strong fundamentals with a P/E of 4.79 and net income margin of 8.7%, while recent Q1 2026 earnings missed expectations. Revenue grew to $1.18 billion in 2025, and the company appointed a new CFO in June 2026.
The stock appears undervalued with a consensus price target of $9.50, offering significant upside potential. However, risks include recent earnings miss, competitive pressures in digital services, and potential market volatility. Analyst sentiment is mixed with 55% buy ratings but cautious technical indicators.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Taskus Inc
TaskUs Inc is a provider of outsourced digital services and next-generation customer experience to innovative and disruptive technology companies. It serves clients in the fastest-growing sectors, including social media, e-commerce, gaming, streaming media, food delivery and ridesharing, HiTech, FinTech and HealthTech.
Read more on TASK →
